Assessment of the Safety and Efficacy of Pramipexole Extended Release in Patients With Parkinson's Disease in Routine Clinical Practice
Phase of Trial: Phase IV
Latest Information Update: 04 Sep 2014
At a glance
- Drugs Pramipexole (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Jan 2013 Planned End Date changed from 1 Apr 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.